This application is for competitive renewal of an established, productive project directed at understanding actions of opioids on gastrointestinal functions. Work supported by this grant in the past provided convincing evidence for brain mediation of some gastrointestinal responses to opioids, identified the spinal cord as one site of opioid action with consequences for gastrointestinal regulation, and provided differentiation of mu, delta and kappa antitransit effects. Recent studies in our laboratory provide evidence that opioids produce a variety of patterns of effects on gastrointestinal motility (contractions) and transit (propulsion). The proposed experiments will test the hypothesis that the specific patterns of motility effects generated by opioids depend on (A) anatomical sites affected (CNS, peripheral, direct) , (B) types of opioid receptors involved at each site (mu, delta, kappa) , (C) region of the gastrointestinal tract studied (stomach, small intestine, cecum and colon), (D) pharmacokinetic properties of the agonists (peptide vs. alkaloid) and therefore on route of administration, (E) unique dose-response relationships, and (F) that endogenous central and peripheral opioids participate in acute and chronic stress responses of the gastrointestinal tract. Moreover, evidence is put forward that certain non-opioid peptides play mediator roles in gastrointestinal responses to opioids. We will employ highly mu, delta and kappa selective opioid agonists and antagonists to determine precisely the effects of opioids on motility after central and peripheral administration and in naive and tolerant animals. We will also determine the relationship between gastrointestinal contractile activity and gastrointestinal transit (propulsion). These data will provide new insight into the actions of opioids with gastrointestinal consequences, will help define brain-gut interactions, and will provide information about regulatory roles of important classes of neuropeptides.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA002163-15
Application #
3207153
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
1978-04-01
Project End
1996-03-31
Budget Start
1993-04-01
Budget End
1994-03-31
Support Year
15
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Bihm, C C; Williams, C L; Burks, T F (1998) Central actions of endomorphins: new endogenous opioids. Proc West Pharmacol Soc 41:81-3
Williams, C L; Rosenfeld, G C; Burks, T F (1997) Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK-B receptor antagonists. Peptides 18:409-14
Shannon, M H; Bihm, C C; Short, W J et al. (1997) Interactions of oxytocin and vasopressin with CRF on the rat colon. Neuropeptides 31:94-8
Williams, C L; Bihm, C C; Rosenfeld, G C et al. (1997) Morphine tolerance and dependence in the rat intestine in vivo. J Pharmacol Exp Ther 280:656-63
Roerig, S C; Williams, C L; Hruby, V J et al. (1996) Inhibition of adenylyl cyclase activity by the cholecystokinin analog SNF 9007 in neuroblastoma x glioma NG108-15 hybrid cells. Regul Pept 61:51-6
Williams, C L; Cody, S; Burks, T F (1994) Stress-induced changes in gastrointestinal transit in mice are dependent on gender. Proc West Pharmacol Soc 37:73-6
Williams, C L; Rosenfeld, G C; Dafny, N et al. (1994) SNF9007: a novel analgesic that acts simultaneously at delta 1, delta 2 and mu opioid receptors. J Pharmacol Exp Ther 269:750-5
Kramer, T H; Davis, P; Hruby, V J et al. (1993) In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. J Pharmacol Exp Ther 266:577-84
Kramer, T H; Toth, G; Haaseth, R C et al. (1991) Influence of peptidase inhibitors on the apparent agonist potency of delta selective opioid peptides in vitro. Life Sci 48:881-6
Ayres, E A; Parkhurst, D N; Fang, S et al. (1991) Antinociceptive and gastrointestinal transit effects of cholecystokinin (CCK-8) and related analogs of CCK-8 in the mouse. Proc West Pharmacol Soc 34:477-84

Showing the most recent 10 out of 79 publications